Free Republic

People who get both Johnson & Johnson’s vaccine and booster shot have high protection levels against the Omicron variant, a new study out of South Africa says. The study released Thursday in pre-print has yet to be peer-reviewed but is promising news for those who received the one-dose vaccine six to nine months ago and who also get a booster from the company. Protection against hospitalization jumped from 63 percent to 85 percent after a second J&J shot, according to the study conducted in November and December among 69,000 vaccinated health care workers. “This data is important given the increased...

The CDC Advisory Committee will be presented new data today. 👀 “…nine deaths related to the issue have also been reported.” https://t.co/5bfwUHGo8y — Ramin Farzaneh-Far MD (@rfsquared) December 16, 2021

Johnson & Johnson’s vaccine produced virtually no antibody protection against the omicron coronavirus variant in a laboratory experiment, underlining the new strain’s ability to get around one pillar of the body’s defenses. The vaccine appears to provide some defense against omicron, perhaps via other means such as stimulation of immune cells, according to Penny Moore, a South African virologist. The findings are consistent with other studies that show a partial loss of potency against COVID-19 for a number of vaccines, with J&J’s antibody protection looking particularly weak in the lab test. Moore, a professor at Johannesburg’s University of The Witwatersrand,...

SNIPThey found that a person who received the vaccine was 3.5 times as likely to develop brain blood clots as an average person before the pandemic.SNIP

People who received Johnson & Johnson's COVID-19 vaccine have higher antibody levels if their booster shot is from Pfizer-BioNTech or Moderna, a new report suggests. The National Institutes of Health (NIH) has allegedly collected data showing that mixing-and-matching is more protective than getting two doses from the New Brunswick, New Jersey-based company, a person who has seen the data told Axios. NIH officials plan to present the findings during a meeting of the U.S. Food and Drug Administration's (FDA) vaccine advisory committee on Friday. It comes as J&J has asked the FDA to approve a shot of its own single-dose...

A number of 49-year-olds who turned up at Croke Park for Janssen (Johnson & Johnson) Covid-19 vaccine appointments on Saturday were turned away due to being under the age of 50, the Health Service Executive (HSE) has confirmed. A HSE spokeswoman said the National Immunisation Advisory Committe (Niac) guidelines stipulate these vaccines are “not recommended for this age group [under 50] at present”. “When this error was identified we immediately made every effort to contact those affected by phone and text to advise them not to attend their appointment today… We sincerely apologise for any inconvenience caused,” she added. Niac...

The federal government’s decision to pause Johnson & Johnson vaccines for 11 days as scientists studied dangerous blood clotting episodes may ultimately boost confidence in vaccine safety, Dr. Anthony Fauci, chief medical adviser to President Joe Biden, said Sunday.

A Mississippi family is demanding answers after 43-year-old Brad Malagerie suffered a mysterious stroke just hours after receiving the Johnson & Johnson COVID-19 vaccine. Malagerie received the vaccine last week after leaving work from his office in D’Iberville around Noon. He went back to work after getting the shot where he was found a few hours later unresponsive, and colleagues had to rush him to the hospital. “They called me and said he had that vaccine and something is wrong, we think it’s a stroke,” said Celeste Foster O’Keefe, Malagarie’s aunt. The hospital found that Malagerie suffered a stroke likely...

President Biden on Tuesday insisted that the feds have enough COVID-19 vaccine supply to blanket the country — after officials put a “pause” on Johnson & Johnson’s one-dose shot. “My message to the American people on the vaccine is, I told y’all. I made sure we have 600 million doses of [Pfizer and Moderna’s vaccines] … not of either Johnson & Johnson and/or AstraZeneca,” the commander in-chief said to reporters at the White House. “So there is enough vaccine, that is basically 100 percent unquestionable for every single solitary American.” Biden’s comments came hours after the FDA and CDC issued...

* U.S. FDA OFFICIAL SAYS ONE DEATH REPORTED DUE TO RARE BLOOD CLOT AFTER J&J VACCINE, ONE PATIENT IS IN CRITICAL CONDITION * U.S. FDA OFFICIAL SAYS HEALTH CARE PROVIDERS WHO SEE WITH EITHER A LOW BLOOD PLATELET COUNT OR BLOOD CLOTS SHOULD ESTABLISH WHETHER INDIVIDUAL HAS RECENTLY BEEN VACCINATED * FOR PEOPLE WHO GOT J&J COVID-19 VACCINE MORE THAN A MONTH AGO, RISK OF BLOOD CLOT EVENTS IS VERY LOW AT THIS TIME- FDA OFFICIAL * WE ARE NOT SEEING CLOTTING EVENTS WITH LOW PLATELET COUNT WITH COVID-19 VACCINES FROM PFIZER/BIONTECH AND MODERNA - CDC OFFICIAL * U.S. FDA...

Federal health agencies on Tuesday will call for an immediate pause in use of Johnson & Johnson’s single-dose coronavirus vaccine after six recipients in the United States developed a rare disorder involving blood clots within about two weeks of vaccination, officials briefed on the decision said. All six recipients were women between the ages of 18 and 48. One woman died and a second woman in Nebraska has been hospitalized in critical condition, the officials said. Nearly seven million people in the United States have received Johnson & Johnson shots so far, and roughly nine million more doses have been...

Allen was thrilled when she was able to book an appointment for the one-dose Johnson & Johnson vaccine at the Javits Center on March 10. The sprawling convention space had just received new shipments of vaccine and was jabbing New Yorkers around the clock — Allen’s appointment was at 2 a.m. As a wine and spirits distributor, she was able to get a coveted early spot even while vaccines remained unavailable to most New Yorkers. Though she experienced a brief fever the next day, her side effects from the jab quickly resolved. Even after Allen was vaccinated, she was careful...

Supplies of Johnson & Johnson’s one-dose coronavirus vaccine will be extremely limited until federal regulators approve production at a Baltimore manufacturing plant under scrutiny, the White House’s pandemic response coordinator said Friday. With allocations of the Johnson & Johnson vaccine set to plunge by 86 percent next week, governors across the country warned that the loss of the supplies they were counting on would set back their vaccination drives, which have used the shot in more transient, isolated and rural areas where the one-dose vaccine has appealed to many Americans. The other two vaccines, made by Moderna and Pfizer-BioNTech, continue...

Johnson & Johnson has backed off a previous pledge to deliver 24 million additional doses of its one-shot vaccine by the end of April amid the continued failure of its troubled contract manufacturer in Baltimore to win government manufacturing certification. With domestic production of the company’s vaccine still unapproved, the government slashed its national allocation of the J&J vaccine to states by 86 percent to just 700,000 doses next week, down from nearly 5 million, a cut that Maryland Gov. Larry Hogan (R) called “very concerning.” The cuts will make it harder across the country for much of April to...

A Georgia vaccine site temporarily shut down Wednesday after eight people suffered serious side effects. The site in Cumming is one of four nationwide to pause injections of the Johnson & Johnson vaccine this week, the Associated Press reported.

TUCSON, Ariz., April 5, 2021 /PRNewswire/ -- More than a dozen countries worldwide temporarily stopped administering the Oxford-AstraZeneca COVID vaccine, notes the Association of American Physicians and Surgeons (AAPS), because of deaths from blood clotting disorders, with either clots or excessive bleeding. Some patients experienced the extremely rare event of clots in the veins that drain blood from the brain (venous sinus thrombosis). Most countries resumed use after a short pause, when the European Medicines Agency (EMA) said the shot isn't associated with an increase in the overall risk of developing blood clots, and the benefits of using the vaccine...

Senior officials in the Trump and Biden administrations knew for months that there were issues with the Baltimore plant that botched 15 million doses of Johnson & Johnson's COVID-19 vaccine (in February), Politico reported.Citing two people with direct knowledge of the issue and an internal report, Politico reported that a document detailing issues with the Emergent BioSolutions plant was sent to Trump officials working on vaccines in June 2020.The report, produced by a government official, warned that the Emergent BioSolutions plant did not have enough staff who could properly oversee vaccine production, and that it had issues with hiring and...

Thirteen people at a COVID-19 vaccination site in Colorado had adverse reactions to the Johnson & Johnson vaccine on Wednesday — shutting down operations for the day, a report said. Officials did not disclose the types of reactions suffered by less than 1 percent of the more than 1,700 people given shots at Dick’s Sporting Goods Park in Commerce City, the Denver Gazette reported. The vaccination effort was being sponsored by the state and Centura Health. More than 600 people with appointments Wednesday were unable to receive their vaccinations after the early closure. “We followed our protocols and in an...

The United States has put Johnson and Johnson in charge of a plant that ruined 15 million doses of its COVID-19 vaccine and has stopped British drugmaker AstraZeneca Plc from using the facility, a senior health official said on Saturday. J&J said it was “assuming full responsibility” of the Emergent BioSolutions facility in Baltimore, reiterating that it will deliver 100 million doses to the government by the end of May. In a separate statement late Sunday, Emergent said it expects to align with the U.S. government and AstraZeneca to ramp down manufacturing for AstraZeneca’s COVID-19 vaccine at its Baltimore plant....

Johnson & Johnson’s single-shot coronavirus vaccine has been recommended for emergency use authorization by an independent advisory committee, setting it up to get the green light from the FDA and mark the third vaccine available in the United States. Johnson & Johnson’s single-dose vaccine protects against COVID-19, according to an analysis by U.S. regulators Wednesday, Feb. 24, 2021, that sets the stage for a final decision on a new and easier-to-use shot to help tame the pandemic. The Food and Drug Administration’s scientists confirmed that overall, it’s about 66% effective and also said J&J’s shot, one that could help speed...